drugset / Trial / NCT07536789
Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate the efficacy and safety of Becotatug vedotin, MRG003, in previously treated advanced hepatocellular carcinoma (HCC).
Timeline
- Start
- 2026-04-17
- Primary completion
- 2028-04-15
- Completion
- 2029-04-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Becotatug Vedotin | Monoclonal antibody | 2.3 mg/kg | Intravenous |